Literature DB >> 10961689

Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.

U Vogt1, B Falkiewicz, K Bielawski, U Bosse, C M Schlotter.   

Abstract

A pilot study on relationships of selected molecular factors [erbB-1, erbB-2, erbB-3, and c-myc oncogene average gene copy numbers (AGCN); steroid receptors and pS2 gene expression; tumor cells' DNA values] to the ex vivo chemosensitivity of ovarian cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed. Despite the relatively small number of patients, numerous correlations among the factors tested were found. Nevertheless, only c-myc gene dosage positively affected ex vivo chemosensitivity of tumors tested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961689

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  4 in total

Review 1.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

2.  G648C variant of DNA polymerase β sensitizes esophageal cancer to chemotherapy.

Authors:  Yuanyuan Wang; Qianqian Sun; Wei Guo; Xiaonan Chen; Yuwen Du; Wenqiao Zang; Ziming Dong; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2015-09-03

Review 3.  Prediction of resistance to chemotherapy in ovarian cancer: a systematic review.

Authors:  Katherine L Lloyd; Ian A Cree; Richard S Savage
Journal:  BMC Cancer       Date:  2015-03-11       Impact factor: 4.430

4.  Overexpression of A613T and G462T variants of DNA polymerase β weakens chemotherapy sensitivity in esophageal cancer cell lines.

Authors:  Yuanyuan Wang; Xiaonan Chen; Qianqian Sun; Wenqiao Zang; Min Li; Ziming Dong; Guoqiang Zhao
Journal:  Cancer Cell Int       Date:  2016-11-10       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.